The 57 references in paper I. PCHELIN Yu., A. SHISHKIN N., O. LAPTEVA A., И. ПЧЕЛИН Ю., А. ШИШКИН Н., О. ЛАПТЕВА А. (2011) “РОЛЬ СИСТЕМНОГО И ЛОКАЛЬНОГО ВОСПАЛЕНИЯ В РАЗВИТИИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ // THE ROLE OF SYSTEMIC AND LOCAL INFLAMMATION IN DIABETIC NEPHROPATHY” / spz:neicon:nefr:y:2011:i:4:p:21-26

1
Шестакова МВ, Шамхалова МШ, Ярек-Мартынова ИЯ и др. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет 2011; (1): 81-88
(check this in PDF content)
2
Jerums G, Premaratne E, Panagiotopoulus S et al. New and old markers of progression of diabetic nephropathy. Diab Res Clin Pract 2008; 82: 30-37
(check this in PDF content)
3
Nosadini R, Tonolo G. Relationship between Blood Glucose Control, Pathogenesis and Progression of Diabetic Nephropathy. J Am Soc Nephrol 2004; 15 [Suppl 1]: S1-S5
(check this in PDF content)
4
Alaveras AEG, Thomas SM, Sagriotis A et al. Promoters of progression of diabetic nephropathy: The relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 1997; 12 [Suppl 2]: 71-74
(check this in PDF content)
5
Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure independent effect. Circulation 2002; 106: 672-678
(check this in PDF content)
6
Karalliedde J, Gnudi L. ACCORD and ADVANCE: A tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant 2008; 23: 1796-1798
(check this in PDF content)
7
Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792
(check this in PDF content)
8
Kelly KJ, Domingues JH. Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J Nephrol 2010; 32: 469-475
(check this in PDF content)
9
Kaul K, Hodgkinson A, Tarr JM. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diab Rev 2010; 6: 294-303
(check this in PDF content)
10
Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94: 3171-3182
(check this in PDF content)
11
Segerer S, Nelson PJ, Schlondorff D. Chemokines, Chemokine Receptors, and Renal Disease: From Basic Science to Pathophysiological and Therapeutic Studies. J Am Soc Nephrol 2000; 11: 152-176
(check this in PDF content)
12
Fornoni A, Ijaz A, Tejada T et al. Role of Inflammation in Diabetic Nephropathy. Curr Diab Rev 2008; 4: 10-17
(check this in PDF content)
13
Navarro-Gonzalez JF, Mora-Fernandez C. The Role of Inflammatory Cytokines in Diabetic Nephropathy. JAm Soc Nephrol 2008; 19: 433-442
(check this in PDF content)
14
Navarro-Gonzalez JF, Mora-Fernandez C. The role of TNF-α in diabetic nephropathy: Pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006; 17: 441-450
(check this in PDF content)
15
Ray A, Huisman MV, Tamsma JT et al. The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus. Eur J Int Med 2009; 20: 253-260
(check this in PDF content)
16
Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7
(check this in PDF content)
17
Dandona P, Chaudhuri A. Anti-inflammatory and antiatherogenic effects of insulin. Insulin 2006; 1 [Suppl 1]: S11-S17
(check this in PDF content)
18
Welsh GI, Hale LJ, Eremina V et al. Insulin Signaling to the Glomerular Podocyte Is Critical for Normal Kidney Function. Cell Metab 2010; 12: 329-340
(check this in PDF content)
19
Hyvonen ME, Saurus P, Wasik A et al. Lipid phosphotase SHIP2 downregulates insulin signaling in podocytes. Moll Cell Endorinol 2010; 328: 70-79
(check this in PDF content)
20
Siragy HM, Awad A, Abadir P et. al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 2003; 144: 2229-2233
(check this in PDF content)
21
Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 2008; 93: 817-824
(check this in PDF content)
22
Theilig F. Spread of glomerular to tubulointerstitial disease with a focus on proteinuria. Ann Anat 2010; 192: 125132
(check this in PDF content)
23
Шишкин АН. Факторы роста и гломерулосклероз при диабетической нефропатии. Нефрология 2005; 9(4): 104107
(check this in PDF content)
24
Li JH, Huang XR, Zhu H-J et al. Role of TGF-β signaling in extracellular matrix production under high glucose conditions. Kidney Int 2003; 63: 2010-2019
(check this in PDF content)
25
Nicholas SB, Liu J, Kim J et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int 2010; 77: 588600
(check this in PDF content)
26
Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-1 Is the Key Activator of TGF-β1 in Human Mesangial Cells Exposed to High Glucose. J Am Soc Nephrol 2001; 12: 703-712
(check this in PDF content)
27
Navarro-Gonzalez JF, Mora-Fernandez C, De Fuentes MM et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340
(check this in PDF content)
28
Moriwaki Y, Yamamoto T, Shibutani Y et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metabolism 2003; 52: 605-608
(check this in PDF content)
29
Zozulinska D, Wierusz-Wysocka B. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res Clin Pract 2006; 74 [Suppl 1]: S12-S16
(check this in PDF content)
30
Wisse BE. The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity. J Am Soc Nephrol 2004; 15: 2792-2800
(check this in PDF content)
31
Navarro-Gonzalez JF, Mora C, Muros M et al. Urinary tumor necrosis factor-α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 2006; 21: 34283434
(check this in PDF content)
32
Navarro-Gonzalez JF, Mora C, Macia M et al. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 2003; 42 [Suppl 2]: 53-61
(check this in PDF content)
33
Dalla Vestra M, Mussap M, Gallina P et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16 [Suppl 1]: S78-S82
(check this in PDF content)
34
Nakamura A, Shikata K, Hiramatsu M et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005; 28: 2890-2895
(check this in PDF content)
35
Aso Y, Yosida N, Okumura K et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 2004; 348: 139-145
(check this in PDF content)
36
Jacobsen P, Tarnow L, Carstensen B et al. Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy. J Am Soc Nephrol 2003; 14: 2843-2850
(check this in PDF content)
37
Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203-214
(check this in PDF content)
38
Raj DSC. Role of Interleukin-6 in the Anemia of Chronic Disease. Semin Arthritis Rheum 2009; 38: 382-388
(check this in PDF content)
39
Lankhorst CE, Wish JB. Anemia in renal disease: Diagnosis and management. Blood Rev 2010; 24: 39-47
(check this in PDF content)
40
Buck I, Morceau F, Grigorakaki C et al. Linking anemia to inflammation and cancer: The crucial role of TNF-α. Biochem Pharmacol 2009; 77: 1572-1579
(check this in PDF content)
41
Пчелин ИЮ, Шишкин АН. Механизмы развития и клиническое значение анемии у пациентов с сахарным диабетом 1 и 2 типа. Вестн. С.-Петерб. ун-та. Сер. 11 2010; (2): 73-80
(check this in PDF content)
42
Silverberg D, Wexler D. Anemia, the fifth major cardiovascular risk factor. Transfus Med Hemotherapy 2004; 31: 175-179
(check this in PDF content)
43
Keane WF, Brenner BM, De Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 2003; 63: 1499-1507
(check this in PDF content)
44
Garcia C, Feve B, Ferre P et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes Metab 2010; 36: 327-338
(check this in PDF content)
45
Navarro-Gonzalez JF, Jarque A, Muros M et al. Tumor necrosis factor-α as a target for diabetic nephropathy. Cytokine Growth Factor Rev 2009; 20: 165-173
(check this in PDF content)
46
Raval G, Mehta P. TNF-α inhibitors: Are they carcinogenic? Drug Health Patient Saf 2010; 2: 241-247
(check this in PDF content)
47
Leyva-Jimenez R, Rodrigues-Orozco AR, OrtegaPierres LE et al. Effect of pentoxifylline on the evolution of diabetic nephropathy. Med Clin 2009; 132: 772-778
(check this in PDF content)
48
McCormick BB, Sydor A, Akbari A et al. The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Diasease: A Meta-analysis. α 2008; 52: 454-463
(check this in PDF content)
49
Navarro-Gonzalez JF, Milena FG, Mora C et al. Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 2005; 68 [Suppl 99]: S98-S102
(check this in PDF content)
50
Navarro-Gonzalez JF, Mora C, Muros M et al. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005; 16: 21192126
(check this in PDF content)
51
Manning PG, Sutherland WHF, Walker RJ et al. The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes Res Clin Pract 2008; 81: 209215
(check this in PDF content)
52
Zheng M, Ye S, Zhai Z. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal monocyte chemoattractant protein-1 expression. J Diabetes Complications 2009; 23: 124-129
(check this in PDF content)
53
Sarafidis PA, Stafylas PC, Georgianos PI. Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis. Am J Kidney Dis 2010; 55: 835-847
(check this in PDF content)
54
Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. J Cardiometab Syndr 2009; 4: 4-9
(check this in PDF content)
55
Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007; 71: 1215-1222
(check this in PDF content)
56
Balakumar P, Arora MK, Ganti SS et al. Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacol Res 2009; 60: 24-32
(check this in PDF content)
57
Danis RP, Sheetz MJ. Ruboxistaurin: PKC-β inhibition for complications of diabetes. Expert Opin Pharmacother 2009; 10: 2913-2925 Ïîñòóïèëà â ðåäàêöèþ 24.10.2011 ã. Ïðèíÿòà â ïå÷àòü 18.11.2011 ã.
(check this in PDF content)